Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL)

Br J Haematol. 2015 May;169(3):449-52. doi: 10.1111/bjh.13224. Epub 2014 Nov 20.

Authors

Adrian Bloor¹, Erwin De Cock, Anthony J Hatswell, Radek Wasiak, Jamie Elvidge, Ceilidh Stapelkamp, Tsveta Hadjivassileva, Amin Haiderali, Julio Delgado

Affiliation

¹ Department of Haematology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.

PMID: 25410960
DOI: 10.1111/bjh.13224

No abstract available

Keywords: alemtuzumab; chronic lymphocytic leukaemia; fludarabine; refractory; therapy costs.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Health Care Costs*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Treatment Outcome